Receptos Provides Update on Progress of Lead Product Candidate RPC1063
June 05, 2013 08:00 ET
|
Receptos, Inc.
Successfully Completes Thorough QT Study
Obtains Special Protocol Assessments (SPAs) From FDA for Phase 3 Trials in Relapsing Multiple Sclerosis
SAN DIEGO, June 5, 2013 (GLOBE NEWSWIRE) --...
Receptos to Present at Jefferies 2013 Global Healthcare Conference
May 29, 2013 16:30 ET
|
Receptos, Inc.
SAN DIEGO, May 29, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos to Deliver Scientific Presentations at Digestive Disease Week 2013 About the Therapeutic Role of RPC1063 in Inflammatory Bowel Disease
May 15, 2013 16:05 ET
|
Receptos, Inc.
SAN DIEGO, May 15, 2013 (GLOBE NEWSWIRE) -- Receptos (Nasdaq:RCPT) today announced that Company personnel will deliver three scientific poster presentations about RPC1063 at the Digestive Disease Week...
Receptos Announces Completion of Initial Public Offering of Common Stock
May 14, 2013 21:39 ET
|
Receptos, Inc.
SAN DIEGO, May 14, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Announces Pricing of Initial Public Offering of Common Stock
May 08, 2013 19:02 ET
|
Receptos, Inc.
SAN DIEGO, May 8, 2013 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...